oncology

Featured image of the article BioNTech, promising results in a clinical trial with a bispecific antibody therapy to treat breast cancer (BNT327).

BioNTech, promising results in a clinical trial with a bispecific antibody therapy to treat breast & lung cancers (BNT327)

Posted on by

SOPHIA ANTIPOLIS, France – February 4th, 2025 (last update 10th April, 2025) │ Advancements in oncology have consistently pushed the boundaries of therapeutic innovation, particularly in the realm of immunotherapy. BioNTech’s BNT327, a bispecific antibody targeting vascular endothelial growth factor (VEGF) and Programmed death-ligand 1 (PD-L1), represents a cutting-edge approach to treating difficult cancers such[…]

Cellectis is a strategic intellectual property partner for AstraZeneca in the field of off-the-shelf immunotherapies

Posted on by

SOPHIA ANTIPOLIS, France – November 02, 2023 │Cellectis and AstraZeneca announced their partnership through a Joint Research Collaboration Agreement, an $80 million initial equity investment, and a memorandum of understanding for an additional $140 million equity investment. The focus of this collaboration is to advance the development of cutting-edge treatments for critical medical conditions in[…]

NKARTA: Recent IP and Promising Results in a Clinical Trial with CD19 CAR- Modified Natural Killer Cells

Posted on by

SOPHIA ANTIPOLIS, France – August 03, 2023 │ Today, immunotherapy is essential in cancer treatment. This field is therefore in full expansion and a lot of innovative therapies are emerging. In 2017, the FDA approval of two CAR-T cells therapies (KYMRIAH™ from Novartis and YESCARTA™ from Kite Pharma, a Gilead company) has enable the development[…]